AbSci is a leading synthetic biology company that translates ideas into drugs with its Integrated Drug Creation(TM) Platform technology that reinvents the biopharmaceutical drug discovery process. We custom engineer our patented SoluPro E. coli expression system to enable discovery of novel next-generation protein-based biologics in their full length format while simultaneously developing optimized production cell lines.

We are deploying cutting edge deep learning artificial intelligence to inform our designs, and every day we succeed in achieving things others have dismissed as impossible. We are continually innovating, expanding the scope of what we can do and the impact we can have as we help get better medicines to patients...sooner.